Related Experiment Video
Updated: Aug 11, 2026
10:05
Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
Published on: July 7, 2016
Digoxin therapy: a clinical pharmacokinetic approach
Scottish Medical Journal
|January 1, 1978
Summary
Optimizing digoxin treatment involves using pharmacokinetic principles and radioimmunoassay to enhance patient care and minimize adverse reactions. Improved pharmaceutical formulations are key to reducing variability in absorption and bioavailability for better dosing.
Area of Science:
- Pharmacology
- Clinical Pharmacy
- Drug Formulation
Background:
- Digoxin is a cardiac glycoside with a narrow therapeutic index.
- Individual patient variability affects digoxin efficacy and safety.
- Optimizing digoxin therapy requires careful consideration of absorption and bioavailability.
Purpose of the Study:
- To outline the scientific basis for individualizing digoxin prescriptions.
- To highlight methods for improving the quality of digoxin treatment.
- To identify strategies for reducing adverse reactions associated with digoxin.
Main Methods:
- Application of pharmacokinetic principles in dosage determination.
- Utilization of digoxin radioimmunoassay for therapeutic drug monitoring.
- Analysis of factors influencing drug bioavailability and absorption.
Main Results:
- Pharmacokinetic principles and radioimmunoassay improve digoxin treatment quality.
- These methods reduce the incidence of adverse reactions.
- Optimized pharmaceutical formulations minimize variations in bioavailability and absorption.
Conclusions:
- Digoxin can be safely prescribed on a scientific basis when individualized.
- Pharmacokinetic and immunoassay approaches enhance therapeutic outcomes.
- Improved drug formulations are crucial for consistent digoxin dosing and patient safety.
Related Concept Videos
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
01:01Dosage Regimens: Partial Pharmacokinetic Parameters
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
01:25Determination of Multiple Dosing Parameters: Loading and Maintenance Doses
A loading dose is an essential pharmacological strategy to rapidly achieve the target plasma drug concentration necessary for an immediate therapeutic effect. This approach is especially critical for drugs characterized by slow absorption or extended half-lives, where delaying therapeutic plasma levels could compromise treatment outcomes. By administering a loading dose, clinicians ensure a prompt onset of drug action, even for agents with complex pharmacokinetic profiles.Achieving steady-state...
01:26Therapeutic Drug Monitoring: Drug Analysis Methods
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood or body tissues to tailor drug therapy effectively. This monitoring is critical for managing drugs with narrow therapeutic indices like digoxin and phenytoin, ensuring they are both safe and effective. For instance, monitoring theophylline levels in asthma patients involves precision and sensitivity to adjust doses according to individual responses to therapy, ensuring efficacy and...
01:14Pharmacokinetic–Pharmacodynamic Relationship: Duration of Dose-Effect Relationship
For drugs producing a quantal response, onset occurs when plasma concentration reaches a minimum effective level (Cmin). The drug's action duration depends on how long the plasma concentration remains above Cmin.Two primary factors influence this duration: dose size and the rate of drug removal from the action site. Both depend on the drug's redistribution to poorly perfused tissues and elimination processes. A larger dose promotes rapid onset and prolongs the effect's duration.Consider a...
01:24Pharmacokinetic–Pharmacodynamic Relationship: Problems
The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...